Please assess the completion status of the following clinical trial:

Trial Title: Retigabine (Adjunctive Therapy) Efficacy and Safety Study for Partial Onset Refractory Seizures in Epilepsy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of refractory epilepsy with simple or complex partial onset seizures with or without secondary generalization~* 28-day partial seizure frequency rate of four or more partial seizures over the 8-week baseline phase~* Currently treated with up to three established AEDs~* Vagal Nerve Stimulator may be included~Exclusion Criteria:~* Existing medical or psychiatric condition which could affect patient's health or compromise ability to participate in the study~* Clinically significant abnormalities on physical exam, vital signs, ECG, or liver function tests~* Impaired renal function (creatinine clearance less than 50 mL/minute)~* Evidence of progressive central nervous disease, lesion, or encephalopathy~* History of primary generalized seizures~* History of clustering or flurries or status epilepticus within 12 months of study entry

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- Retigabine (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).